Overview

* Y-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectations

* SERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025

* Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19

Outlook

* Y-mAbs did not provide further guidance due to pending acquisition

* Company to be acquired by SERB Pharmaceuticals by Q4 2025

Result Drivers

* U.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competition

* EX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern Asia

* LICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in Israel

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $19.50

Product mln

Revenue

Q2 EPS Beat -$0.07 -$0.27

(9

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc ( YMAB ) is $8.60, about 0.9% above its August 7 closing price of $8.52

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)